Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant Driving Performance Study in MDD
NCT04451187Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Standard Deviation of Lateral Position at Day 2. Started Jul 2020; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04451187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451187.